#1 Clinical Trials Search in Europe

Lixudebart

Lixudebart, also known as ALE.F02, is an investigational drug being studied for the treatment of rapidly progressive glomerulonephritis (RPGN) associated with antineutrophil cytoplasmic antibody (ANCA) vasculitis. This article explores the ongoing clinical trials evaluating the safety, tolerability, and potential benefits of Lixudebart in preserving kidney function for patients with this serious condition.

Table of Contents

What is LIXUDEBART?

LIXUDEBART, also known by its product code ALE.F02, is a new medication being studied for the treatment of a serious kidney condition[1]. It is a type of drug called a monoclonal antibody, which is a laboratory-made protein that can target specific substances in the body[1]. LIXUDEBART is specifically designed to target a protein called Claudin 1, which is found in the body[1].

Medical Conditions Treated

LIXUDEBART is being studied to treat a condition called Rapidly Progressive Glomerulonephritis (RPGN) that is caused by ANCA-Associated Vasculitis (AAV)[1]. Let’s break down these terms:

  • Rapidly Progressive Glomerulonephritis (RPGN): This is a serious kidney disease where the kidneys’ filtering units (glomeruli) become inflamed and damaged very quickly, leading to rapid loss of kidney function[1].
  • ANCA-Associated Vasculitis (AAV): This is an autoimmune disease where the body’s immune system mistakenly attacks and inflames small blood vessels. ANCA stands for Anti-Neutrophil Cytoplasmic Antibody, which is a type of antibody found in this condition[1].

How LIXUDEBART Works

While the exact mechanism of action is not fully described in the provided information, LIXUDEBART is designed to target Claudin 1, a protein that may play a role in the disease process of RPGN and AAV. By targeting this protein, researchers hope that LIXUDEBART can help preserve kidney function and reduce inflammation in patients with these conditions[1].

Clinical Trial Details

LIXUDEBART is currently being studied in a clinical trial called “REscue of Nephrons with ALe.F02 (RENAL F02)”[1]. This is a Phase 2 trial, which means it’s testing the drug’s effectiveness and safety in a larger group of patients. The trial is:

  • Randomized: Patients are randomly assigned to receive either LIXUDEBART or a placebo.
  • Double-blind: Neither the patients nor the doctors know who is receiving the actual drug or the placebo.
  • Placebo-controlled: Some patients receive a placebo (a substance with no active drug) to compare the effects with those who receive LIXUDEBART.

Eligibility Criteria

The trial has specific criteria for who can participate. Some key points include[1]:

  • Patients must be 18 years or older
  • Recently diagnosed with RPGN (within 45 days before starting the study treatment)
  • Have evidence of kidney function loss
  • Test positive for ANCA (anti-MPO or anti-PR3)
  • Not have certain other medical conditions that could interfere with the study

Safety and Effectiveness

The main goal of this study is to assess how safe LIXUDEBART is and how well patients tolerate it[1]. Researchers will be looking at:

  • Side effects (called adverse events)
  • Changes in blood tests
  • Whether patients develop antibodies against the drug
  • Changes in heart rhythm (ECGs)

The study will also look at how effective LIXUDEBART is by measuring[1]:

  • Changes in kidney function
  • Changes in protein levels in urine
  • How quickly signs of kidney damage (like protein and blood in urine) improve
  • Whether patients need kidney replacement therapy (like dialysis)
  • How much other medications (like steroids) patients need

Administration and Dosage

LIXUDEBART is given as an intravenous infusion, which means it’s delivered directly into the bloodstream through a vein[1]. The maximum daily dose being studied is 15 mg per kilogram of body weight, and the total maximum dose over the treatment period is 195 mg/kg[1]. The treatment period lasts for 24 weeks[1].

Aspect Details
Drug Name Lixudebart (ALE.F02)
Trial Type Phase 2, randomized, double-blind, placebo-controlled study
Condition Studied Rapidly Progressive Glomerulonephritis (RPGN) due to ANCA-Associated Vasculitis
Primary Objective Assess safety and tolerability of Lixudebart
Key Secondary Objective Evaluate change in mean eGFR from baseline to Week 24
Administration Method Continuous intravenous infusion
Maximum Daily Dose 15 mg/kg
Treatment Duration Up to 24 weeks
Key Inclusion Criteria Adults ≥18 years, newly diagnosed RPGN within 45 days, eGFR 10-50 mL/min/1.73 m², positive ANCA test
Key Exclusion Criteria Previous RPGN history, recent dialysis or plasma exchange, active infections, malignancy within 5 years

FAQ

  • What is Lixudebart and how does it work? Lixudebart is a humanized monoclonal antibody that targets a protein called Claudin 1. It is designed to potentially help preserve kidney function in patients with rapidly progressive glomerulonephritis caused by ANCA-associated vasculitis.
  • What is the main goal of the clinical trial for Lixudebart? The primary objective of the trial is to assess the safety and tolerability of Lixudebart when given as a continuous intravenous infusion to patients with rapidly progressive glomerulonephritis attributed to ANCA-associated vasculitis.
  • Who can participate in the Lixudebart clinical trial? Eligible participants are adults (18 years or older) newly diagnosed with rapidly progressive glomerulonephritis within 45 days prior to starting treatment. They must have evidence of kidney function loss and a positive test for ANCA antibodies.
  • How is Lixudebart administered in the trial? Lixudebart is given as a continuous intravenous infusion. The maximum daily dose is 15 mg/kg, with a total maximum dose of 195 mg/kg over a treatment period of up to 24 weeks.
  • What are the potential benefits of participating in this trial? Participants may benefit from potentially improved kidney function and reduced need for immunosuppressive medications. The trial aims to evaluate if Lixudebart can help preserve kidney function over time when added to standard care for rapidly progressive glomerulonephritis.

Ongoing Clinical Trials on Lixudebart

  • Study on the Safety and Tolerability of Lixudebart and Rituximab for Patients with Rapidly Progressive Glomerulonephritis Due to ANCA-Associated Vasculitis

    Recruiting

    1 1
    Investigated drugs:
    Czechia Denmark France Germany Italy Spain +1

Glossary

  • Rapidly Progressive Glomerulonephritis (RPGN): A severe kidney disease characterized by rapid loss of kidney function, often within days to weeks. It is caused by inflammation in the kidney's filtering units (glomeruli).
  • ANCA-Associated Vasculitis (AAV): A group of autoimmune disorders that cause inflammation of small blood vessels, often affecting the kidneys. ANCA stands for antineutrophil cytoplasmic antibody, which is found in the blood of people with this condition.
  • Monoclonal Antibody: A type of protein made in the laboratory that can bind to specific targets in the body. Lixudebart is a monoclonal antibody designed to target a specific protein involved in kidney inflammation.
  • eGFR: Estimated Glomerular Filtration Rate, a measure of how well the kidneys are filtering waste from the blood. It is used to assess kidney function and track changes over time.
  • Intravenous Infusion: A method of delivering medication directly into a vein using a needle or catheter, allowing the drug to enter the bloodstream quickly.
  • Proteinuria: The presence of excess protein in the urine, which can be a sign of kidney damage or disease.
  • Hematuria: The presence of blood in the urine, which can be a sign of kidney or urinary tract problems.
  • Renal Biopsy: A medical procedure where a small sample of kidney tissue is removed and examined under a microscope to diagnose kidney diseases.
  • Immunosuppressant: A type of medication that reduces the activity of the immune system, often used to treat autoimmune diseases or prevent organ rejection after transplantation.
  • Glucocorticoids: A class of steroid hormones that reduce inflammation and suppress the immune system, commonly used in the treatment of autoimmune diseases.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-tolerability-of-lixudebart-and-rituximab-for-patients-with-rapidly-progressive-glomerulonephritis-due-to-anca-associated-vasculitis/